Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Double-blind, Randomized, Placebo-controlled, Six-arm, Parallel-group, Dose-finding Trial to Determine Efficacy, Safety and Tolerability of Five Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

NCT00243217 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00243217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00243217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Double-blind, Randomized, Placebo-controlled, Six-arm, Parallel-group, Dose-finding Trial to Determine Efficacy, Safety and Tolerability of Five Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
February 29, 2004
Enrollment
341 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic restless leg syndrome